[Involvement of Aldosterone and mineralocorticoid receptor in pathogenesis of cardiovascular diseases].
Miyamori
Isamu
I
Third Department of Internal Medicine, Fukui Medical University.
D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000502:physiology; D000450:Aldosterone / Q000494:pharmacology / Q000502:physiology*; D000804:Angiotensin II / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology*; D005355:Fibrosis; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009206:Myocardium / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000502:physiology*; D013148:Spironolactone / Q000627:therapeutic use
D000451:Mineralocorticoid Receptor Antagonists; D017395:Plasminogen Activator Inhibitor 1; D044140:Receptor, Angiotensin, Type 1; D018161:Receptors, Mineralocorticoid; D000804:Angiotensin II; D013148:Spironolactone; D000450:Aldosterone; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; D006854:Hydrocortisone